HC Wainwright Has Positive View of Scholar Rock Q2 Earnings

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Equities research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for shares of Scholar Rock in a note issued to investors on Friday, May 8th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.81) per share for the quarter, up from their previous forecast of ($0.91). HC Wainwright has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($3.11) per share. HC Wainwright also issued estimates for Scholar Rock’s Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($3.21) EPS, FY2027 earnings at ($2.32) EPS and FY2028 earnings at ($0.77) EPS.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the business earned ($0.67) earnings per share.

A number of other equities analysts have also recently issued reports on SRRK. Wedbush increased their target price on Scholar Rock from $56.00 to $58.00 and gave the stock an “outperform” rating in a report on Wednesday, April 1st. BMO Capital Markets increased their target price on Scholar Rock from $50.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, March 4th. Citigroup increased their target price on Scholar Rock from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Barclays increased their target price on Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a report on Tuesday, March 3rd. Five equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Scholar Rock presently has a consensus rating of “Buy” and a consensus price target of $56.00.

Scholar Rock Trading Down 0.1%

Scholar Rock stock opened at $48.35 on Tuesday. The business has a 50 day moving average price of $46.25 and a two-hundred day moving average price of $43.28. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.41. The stock has a market cap of $5.79 billion, a price-to-earnings ratio of -13.47 and a beta of 0.70. Scholar Rock has a 12 month low of $27.07 and a 12 month high of $51.63.

Institutional Investors Weigh In On Scholar Rock

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Siren L.L.C. increased its holdings in Scholar Rock by 17.0% during the 4th quarter. Siren L.L.C. now owns 10,825,013 shares of the company’s stock valued at $476,842,000 after purchasing an additional 1,575,008 shares in the last quarter. Wellington Management Group LLP boosted its position in Scholar Rock by 26.7% in the 4th quarter. Wellington Management Group LLP now owns 5,759,428 shares of the company’s stock valued at $253,703,000 after buying an additional 1,213,541 shares during the last quarter. Vanguard Group Inc. boosted its position in Scholar Rock by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 5,195,465 shares of the company’s stock valued at $228,860,000 after buying an additional 280,538 shares during the last quarter. State Street Corp boosted its position in Scholar Rock by 7.2% in the 4th quarter. State Street Corp now owns 4,034,434 shares of the company’s stock valued at $177,717,000 after buying an additional 271,331 shares during the last quarter. Finally, Orbis Allan Gray Ltd boosted its position in Scholar Rock by 1,034.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 3,428,929 shares of the company’s stock valued at $151,044,000 after buying an additional 3,126,677 shares during the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Akshay Vaishnaw sold 12,246 shares of the firm’s stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $607,034.22. Following the completion of the sale, the insider directly owned 630,542 shares of the company’s stock, valued at $31,255,966.94. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO David Hallal sold 30,615 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $1,517,585.55. Following the sale, the chief executive officer directly owned 1,639,034 shares of the company’s stock, valued at $81,246,915.38. This represents a 1.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 102,736 shares of company stock worth $4,977,900. 13.30% of the stock is currently owned by insiders.

Trending Headlines about Scholar Rock

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: HC Wainwright increased Scholar Rock’s earnings estimates for Q2 2026, Q3 2026, Q4 2026, and FY2026, signaling improving short-term expectations. HC Wainwright Predicts Stronger Earnings for Scholar Rock
• Positive Sentiment: The analyst kept a Buy rating on Scholar Rock and maintained a $65 price objective, implying meaningful upside from current levels. HC Wainwright Predicts Stronger Earnings for Scholar Rock
• Neutral Sentiment: Scholar Rock’s short interest report showed 0 shares of short interest, which does not provide a clear signal for stock direction. Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Rating of “Buy” by Analysts
• Negative Sentiment: HC Wainwright lowered its FY2027 and FY2028 EPS forecasts, indicating some caution about longer-term profitability. HC Wainwright Predicts Stronger Earnings for Scholar Rock

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).